The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.
The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...
An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained free of ...
J&J acquired rights to TAR-200 when it bought privately-owned biotech Taris for an undisclosed sum in 2019, and has big sales ...
ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced significant progress in its ongoing ...
ImmunityBio, Inc. (NASDAQ:IBRX) released progress in its ongoing FDA discussions regarding three areas of its clinical ...
(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...
Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.
The antibody treatment, sasanlimab, in combination with Bacillus Calmette-Guérin (BCG) vaccine met the main goal of the study in patients with high-risk non-muscle invasive bladder cancer (NMIBC ...
Pfizer's Bladder Cancer Therapy Meets Main Goal in Late-Stage Study (Reuters) -Pfizer's experimental treatment for a type of bladder cancer significantly improved the time that patients remained ...